XML 30 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Business Segment
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Business Segment Business Segment
We account and report for our business as a single operating segment entity engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company derives revenue globally and manages the business on a consolidated basis due to shared infrastructure and resources. Our chief operating decision maker ("CODM"), the President and Chief Executive Officer, evaluates the various global product portfolios on a net sales basis and evaluates profitability, investment, cash flow metrics and allocates resources on a consolidated worldwide basis.
Our product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine and lower extremities instrumentation and implants, small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and fees related to sales representation, promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, clinical insufflation, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. These product lines' net sales are as follows:
Three Months Ended March 31,
 20252024
Orthopedic surgery$138,290 $134,912 
General surgery182,966 177,361 
Consolidated net sales$321,256 $312,273 
The following table includes significant segment expenses for the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
20252024
Net sales
$321,256 $312,273 
Cost of sales
143,504 140,308 
Salesforce and commission expense
57,432 55,277 
Marketing expense
15,874 15,521 
Distribution expense
12,033 11,967 
General and administrative expense
32,655 31,840 
Stock-based compensation expense
13,863 6,240 
Amortization expense
7,172 7,152 
Non-cash adjustments to fair value of contingent consideration liability3,962 (6,545)
Research and development expense
12,947 13,594 
Interest expense
8,286 9,594 
Provision for income taxes
1,636 5,710 
Other segment items(a)
5,856 1,906 
Net income
$6,036 $19,709 
(a)Other segment items consist of (i) third party services pertaining to review of potential issues with certain royalty payments to surgeons involved in design teams in 2025 and 2024; (ii) cash compensation costs related to advisory services provided by our former Chief Executive Officer in 2025; (iii) consulting fees in 2025; (iv) gain on the sale of a product line in 2025; and (v) restructuring related costs and income related to the termination of a distributor agreement in 2024.
Total assets for the Company's single operating segment are the same as presented on the Company's consolidated balance sheet, which is used to measure segment performance.